Want to see STTK full AI Analyst Report?
STTK Stock Chart & Stats
$7.53
>-$0.01(-0.39%)
At close: 4:00 PM EST
$7.53
>-$0.01(-0.39%)
Day’s Range― - ―
52-Week Range$0.71 - $8.33
Previous CloseN/A
Volume43.14K
Average Volume (3M)1.56M
Market Cap
$635.32M
Enterprise Value$139.53M
Total Cash (Recent Filing)$90.42M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Aug 06, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding90,372,390
10 Day Avg. Volume2,416,004
30 Day Avg. Volume1,563,276
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.08
Price to Sales (P/S)253.99
P/FCF Ratio-6.36
Enterprise Value/Market Cap0.22
Enterprise Value/Revenue139.53
Enterprise Value/Gross Profit-16.54
Enterprise Value/Ebitda-3.02
Forecast
1Y Price Target
$15.80Price Target Upside109.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Progress (SL-325)Robust Phase 1 human data materially lowers clinical risk for SL-325 by demonstrating target engagement, durability and a clean safety signal. That increases probability of success in the planned Phase 2b Crohn’s trial, supports downstream partnering/licensing discussions, and strengthens long-term asset potential for the inflammatory franchise.
Conservative Capital StructureVery low debt provides financial flexibility to fund R&D and clinical programs without interest pressure, reducing bankruptcy risk. This structural balance-sheet strength gives management more strategic optionality to advance pipeline milestones or pursue partnerships before reaching critical funding constraints.
Platform & Pipeline BreadthA platform-based approach (ARC) creates multiple independent development opportunities and improves scalability of R&D investment. Platform breadth plus multiple candidates (e.g., SL-325, SL-846) raises the firm’s odds of a successful commercial asset, supports licensing/partnering, and makes long-term value less binary.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow indicates ongoing reliance on external financing to sustain clinical development. While burn has improved versus prior years, the company remains far from cash-flow break-even, which creates execution risk if capital markets tighten or expected financings underperform.
Minimal Commercial RevenueVery low and volatile revenue alongside large losses means the business lacks a self-sustaining commercial engine. Dependence on grant, milestone or financing cash inflows increases funding uncertainty and amplifies dilution or program prioritization choices, constraining long-term margin sustainability.
Dilution Risk From FinancingsFrequent equity raises and pre-funded warrants signal ongoing capital needs and can materially dilute existing shareholders. Over the long term, repeated dilution reduces per-share economic upside, can compress returns for investors, and may shift management focus toward financing cadence over operational efficiency.
Shattuck Labs News
STTK FAQ
What was Shattuck Labs, Inc.’s price range in the past 12 months?
Shattuck Labs, Inc. lowest stock price was $0.71 and its highest was $8.33 in the past 12 months.
What is Shattuck Labs, Inc.’s market cap?
Shattuck Labs, Inc.’s market cap is $635.32M.
When is Shattuck Labs, Inc.’s upcoming earnings report date?
Shattuck Labs, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Shattuck Labs, Inc.’s earnings last quarter?
Shattuck Labs, Inc. released its earnings results on May 07, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.138 by $0.008.
Is Shattuck Labs, Inc. overvalued?
According to Wall Street analysts Shattuck Labs, Inc.’s price is currently Undervalued.
Does Shattuck Labs, Inc. pay dividends?
Shattuck Labs, Inc. does not currently pay dividends.
What is Shattuck Labs, Inc.’s EPS estimate?
Shattuck Labs, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Shattuck Labs, Inc. have?
Shattuck Labs, Inc. has 90,372,390 shares outstanding.
What happened to Shattuck Labs, Inc.’s price movement after its last earnings report?
Shattuck Labs, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.138. Following the earnings report the stock price went down -6.287%.
Which hedge fund is a major shareholder of Shattuck Labs, Inc.?
Currently, no hedge funds are holding shares in STTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shattuck Labs Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.80 (109.83% Upside)
$15.80 (109.83% Upside)
Blogger Sentiment
Bullish
STTK Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $250.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 16.3%
Last 30 Days ▲ 16.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
753.15%
12-Months-Change
Fundamentals
Return on Equity
-60.73%
Trailing 12-Months
Asset Growth
32.34%
Trailing 12-Months
Company Description
Shattuck Labs, Inc.
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
STTK Stock 12 Month Forecast
Average Price Target
$15.80
▲(109.83% Upside)
Technical Analysis
Ownership Overview
24.55% Insiders
12.27% Mutual Funds
0.05% Other Institutional Investors
57.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---